Survodutide (BI-456906) is a glucagon and glucagon-like peptide 1 (GLP-1) receptor (GLP Receptor) agonist.
BI 456906 is a once-weekly, injectable GCGR/GLP-1R dual agonist currently in Phase II clinical development for obesity, type 2 diabetes, and NASH. This research describe biomarkers that were applied in the discovery of BI 456906 as a balanced dual agonist and demonstrate that engagement of both the GCGR and GLP-1R achieves a bodyweight-lowering efficacy exceeding that of a selective GLP-1R agonist. Applying mRNA sequencing, researchers provide novel insights into potential mechanisms of action of BI 456906 in hepatocytes, offering a scientific rationale that is supportive of the clinical development for BI 456906 in people with NASH. [1]
Survodutide (BI 456906) is a unimolecular dual agonist of the glucagon and GLP-1 receptors. In addition to anorexigenic effects of GLP-1 receptor stimulation, glucagon receptor agonism may directly elicit hepatic fat loss by increasing energy expenditure, decrease hepatic inflammation by improving mitochondrial function, and impact hepatic fibrosis by reducing stellate cell activation.
Sale!
SURVODUTIDE SUR5 ( SUR5,SUR10)
Chemical. CAS: 2805997-46-8. Formula: C192H289N47O61. MW: 4231.7. Soluble in water (10mg/ml). Survodutide is a novel long-acting dual glucagon-like peptide-1 (GLP-1) receptor and glucagon receptor (GCGR) agonist. Survodutide potently activates the GLP-1R signaling pathway to stimulate glucose-dependent insulin secretion through activity at the GCG receptor (GCGR) or the GLP-1R. Survodutide is a synthetic peptide glucagon analog rather than an analog of oxyntomodulin, unlike other dual GLP-1/glucagon dual agonists. Survodutide binds human and mouse GCGR and GLP-1R and stimulates insulin secretion in isolated mouse, rat and perifused human pancreatic islets. Survodutide is used in studies of obesity and type 2 diabetes (T2D) and is designed enhancing energy expenditure and fat metabolism and decreasing food intake. Survodutide comprises a 29 amino acid linear synthetic peptide conjugated to a C18 fatty diacid moiety through a hydrophilic linker at the lysine residue at position 24. Due to this moiety, the compound is highly bound to albumin in the plasma which prolongs its half-life. It contains one non-coded amino acid residue (Ac4c, 1-Aminocyclobutane-1-carboxylic acid) at position 2, well established as the site of proteolytic activity for dipeptidyl peptidase-4.
Molecular Formula:
C192H289N47O61
Molecular Weight:
4231.7
Package Type:
Vial
Product Description:
Survodutide is a novel long-acting dual glucagon-like peptide-1 (GLP-1) receptor and glucagon receptor (GCGR) agonist. Survodutide potently activates the GLP-1R signaling pathway to stimulate glucose-dependent insulin secretion through activity at the GCG receptor (GCGR) or the GLP-1R. Survodutide is a synthetic peptide glucagon analog rather than an analog of oxyntomodulin, unlike other dual GLP-1/glucagon dual agonists. Survodutide binds human and mouse GCGR and GLP-1R and stimulates insulin secretion in isolated mouse, rat and perifused human pancreatic islets. Survodutide is used in studies of obesity and type 2 diabetes (T2D) and is designed enhancing energy expenditure and fat metabolism and decreasing food intake. Survodutide comprises a 29 amino acid linear synthetic peptide conjugated to a C18 fatty diacid moiety through a hydrophilic linker at the lysine residue at position 24. Due to this moiety, the compound is highly bound to albumin in the plasma which prolongs its half-life. It contains one non-coded amino acid residue (Ac4c, 1-Aminocyclobutane-1-carboxylic acid) at position 2, well established as the site of proteolytic activity for dipeptidyl peptidase-4.
Purity:
>98% (HPLC)
Sequence:
H-His-{Ac4c}-Gln-Gly-Thr-Phe-Thr-Ser-Asp-Tyr-Ser-Lys-Tyr-Leu-Asp-Glu-Arg-Ala-Ala-Lys-Asp-Phe-Ile-{diacid-C18-gamma-Glu-Gly-Ser-Gly-Ser-Gly-Gly-Lys}-Trp-Leu-Glu-Ser-Ala-NH2
Reviews
There are no reviews yet.